mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI
will receive 6 cycles of neoadjuvant treatment with mFOLFOX6 (Arm A) vs. mFOLFOX6 +
aflibercept (Arm B) followed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
AIO-Studien-gGmbH
Collaborators:
Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt Sanofi